Biodesix, Inc. announced preliminary Q4 2025 revenue of $28.8 million (41% increase) and full-year 2025 revenue of $88.5 million (24% increase). The company affirmed guidance for Adjusted EBITDA positivity in Q4 2025. Management will participate in investor conferences in March 2026.
Biodesix, Inc. Common Stock (BDSX)
Common Stock · Currency in USD · XNAS
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Company Info
SIC8071
Composite FIGIBBG001J2LMV6
CIK0001439725
IPOOct 28, 2020
Sectorservices-medical laboratories
Highlights
Market Cap$148.57M
EPS-$4.64
P/E Ratio-4.26
Revenue$83.57M
Gross Profit$87.07M
Net Income-$34.86M
Employees334
WSO9,858,358
Phone303-417-0500
Websitehttps://www.biodesix.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Biodesix, Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Biodesix, Inc. Common Stock (BDSX) has returned 122.93% so far this year and 37.00% over the past 12 months. Looking at the last ten years, BDSX has achieved an annualized return of -25.12%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
BDSX
1M-1.63%
6M94.45%
YTD122.93%
1Y37.00%
5Y-47.47%
10Y-25.12%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Biodesix, Inc. Common Stock (BDSX) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 50.44% | 54.69% | -0.15% | 4.07% | ||||||||
| 2025 | -32.24% | -20.70% | -24.67% | -15.44% | -43.49% | -5.96% | 24.85% | 23.19% | -10.76% | -8.57% | 22.49% | -15.84% |
| 2024 | 12.99% | -25.24% | -24.74% | -13.89% | 16.26% | 5.52% | 8.22% | 16.67% | -10.10% | -5.03% | -13.77% | 6.25% |
| 2023 | 5.73% | -15.57% | -9.71% | -5.98% | -15.15% | -12.14% | -7.03% | 28.69% | 3.13% | -10.69% | 3.47% | 22.67% |
| 2022 | -23.71% | -40.35% | -26.84% | -5.29% | -8.64% | 10.81% | 25.00% | -13.70% | -32.09% | -20.47% | 90.97% | 42.86% |
| 2021 | 19.94% | -19.98% | 0.15% | -19.65% | -11.24% | -8.71% | -28.92% | -3.84% | -9.47% | -8.27% | -8.46% | -23.33% |
| 2020 | -8.54% | 43.52% | 12.37% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Biodesix, Inc. Common Stock (BDSX) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of BDSX compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Biodesix, Inc. Common Stock volatility is 5.53%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 87.48M | 99.10M | 92.91M | 76.10M | 121.07M |
| Equity Attributable To Parent (USD) | -2.47M | 4.58M | 20.61M | 19.73M | 41.17M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - |
| Equity (USD) | -2.47M | 4.58M | 20.61M | 19.73M | 41.17M |
| Other Non-current Liabilities (USD) | 22.50M | 21.02M | 19.33M | 17.34M | 19.70M |
| Long-term Debt (USD) | 50.01M | 40.08M | 30.13M | 10.08M | 28.08M |
| Noncurrent Liabilities (USD) | 72.51M | 61.10M | 49.46M | 27.41M | 47.78M |
| Other Current Liabilities (USD) | 6.52M | 26.63M | 16.48M | 23.27M | 19.19M |
| Wages (USD) | 7.83M | 3.86M | 4.67M | 4.03M | 3.98M |
| Accounts Payable (USD) | 3.08M | 2.93M | 1.69M | 1.66M | 8.96M |
| Current Liabilities (USD) | 17.44M | 33.42M | 22.84M | 28.96M | 32.13M |
| Liabilities (USD) | 89.94M | 94.52M | 72.30M | 56.37M | 79.90M |
| Other Non-current Assets (USD) | 26.26M | 23.64M | 23.93M | 16.69M | 18.49M |
| Intangible Assets (USD) | 3.88M | 7.91M | 9.80M | 11.62M | 13.26M |
| Fixed Assets (USD) | 24.82M | 27.87M | 5.85M | 4.18M | 3.18M |
| Noncurrent Assets (USD) | 54.96M | 59.41M | 39.57M | 32.48M | 34.93M |
| Current Assets (USD) | 32.52M | 39.68M | 53.33M | 43.61M | 86.14M |
| Assets (USD) | 87.48M | 99.10M | 92.91M | 76.10M | 121.07M |
News and Insights
Biodesix reported estimated Q4 2025 revenue of $28.8 million (41% increase) and full-year 2025 revenue of $88.5 million (24% increase). The company affirmed guidance for Adjusted EBITDA positivity in Q4 and plans to present clinical utility data for its Nodify Lung tests at upcoming scientific meetings.
Biodesix reported Q4 2025 revenue of $28.8 million (41% increase) and full-year revenue of $88.5 million (24% increase), exceeding guidance. Lung Diagnostics revenue grew 47% in Q4 driven by increased test volumes and reimbursement expansion. The company affirmed expectations for positive Adjusted EBITDA in Q4 2025.
Biodesix's CFO Robin Cowie will host investor meetings at the Lake Street Capital Markets' 9th Annual Best Ideas Growth Conference in New York on September 11, 2025.
Biodesix will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, with CEO Scott Hutton and CFO Robin Cowie hosting a fireside chat and investor meetings in Boston, MA.
Biodesix will release its second quarter 2025 financial results on August 7, hosting a conference call and webcast to discuss financial performance and provide a business update.
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATSpositive
Biodesix, a diagnostic solutions company, announced that new data from two studies will be presented at upcoming conferences. The studies highlight challenges in managing lung nodules and the potential of Biodesix's tests to guide clinical decision-making.
Biodesix, a leading diagnostic solutions company, announced its financial results for the first quarter of 2025 and will host a conference call to discuss the results and provide a business update.
Biodesix and Bio-Rad Laboratories contributed to research findings from Friends of Cancer Research's ctMoniTR Project, published in Clinical Cancer Research. The findings demonstrate a strong association between changes in circulating tumor DNA (ctDNA) levels and treatment outcomes, offering potential for integration of ctDNA analysis in therapeutic development and clinical cancer care.
Biodesix reported strong financial results for fiscal year 2024, with total revenue of $71.3 million, a 45% increase over the previous year, and gross margins of 78%. The company expects continued growth in 2025, with revenue guidance of $92-95 million.